| dc.contributor.author | Buyukberber, S. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Buyukunal, E. | |
| dc.contributor.author | Camci, C. | |
| dc.contributor.author | Sencan, O. | |
| dc.contributor.author | Yalcin, S. | |
| dc.contributor.author | Uslu, R. | |
| dc.contributor.author | Dane, F. | |
| dc.contributor.author | Yilmaz, U. | |
| dc.contributor.author | Zengin, N. | |
| dc.date.accessioned | 2021-03-06T10:10:51Z | |
| dc.date.available | 2021-03-06T10:10:51Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., "Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial", JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.other | av_e9244b41-9277-47cc-a657-8043d4115b32 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/153201 | |
| dc.identifier.uri | https://doi.org/10.1200/jco.2011.29.15_suppl.3579 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 29 | |
| dc.identifier.issue | 15 | |
| dc.contributor.firstauthorID | 200449 | |
